102TiP A phase III randomised controlled trial of zongertinib (BI 1810631) compared with standard of care (SoC) in patients (pts) with locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) harbouring HER2 tyrosine kinase domain (TKD) mutations: Beamion LUNG-2

Y-L Wu,M.L Johnson,R.A Soo,N Baktash,D Maier,S Eigenbrod-Giese,T Yoshida

doi:10.1016/j.esmoop.2024.102681

102TiP A phase III randomised controlled trial of zongertinib (BI 1810631) compared with standard of care (SoC) in patients (pts) with locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) harbouring HER2 tyrosine kinase domain (TKD) mutations: Beamion LUNG-2

Y-L Wu, M.L Johnson + Show 5 more

Open Access

https://doi.org/10.1016/j.esmoop.2024.102681

Copy DOI

Journal: ESMO Open	Publication Date: Mar 1, 2024
License type: cc-by-nc-nd

#Metastatic Non-squamous Non-small Cell Lung #Non-squamous Non-small Cell Lung Cancer + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

102TiP A phase III randomised controlled trial of zongertinib (BI 1810631) compared with standard of care (SoC) in patients (pts) with locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) harbouring HER2 tyrosine kinase domain (TKD) mutations: Beamion LUNG-2

Full Text